- Home
- ASND
ASND
Ascendis Pharma A/S
as 12-17-2024 4:00pm EST
Ascendis Pharma AS is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.
| Founded: | 2006 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 7.7B | IPO Year: | 2015 |
| Target Price: | $191.77 | AVG Volume (30 days): | 427.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $111.09 - $161.00 | Next Earning Date: | 02-05-2025 |
| Revenue: | $365,187,374 | Revenue Growth: | 115.54% |
| Revenue Growth (this year): | 7.33% | Revenue Growth (next year): | 83.72% |
Latest Ascendis Pharma A/S News
ASND Breaking Stock News: Dive into ASND Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26
MT Newswires
5 days ago
Ascendis Pharma's Supplemental BLA for Adult Growth Hormone Deficiency Drug Accepted by FDA
GlobeNewswire
6 days ago
FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
Simply Wall St.
6 days ago
Exploring Three High Growth Tech Stocks in the United States
Pharmaceutical Technology
7 days ago
Er-Kim and Ascendis’ endocrine therapy agreement extended in Eurasia
MT Newswires
a month ago
Ascendis Pharma Q3 Loss Narrows, Revenue Rises
GlobeNewswire
a month ago
Ascendis Pharma Reports Third Quarter 2024 Financial Results
GlobeNewswire
a month ago
Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
Compare ASND vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ASND Ascendis Pharma A/S - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.